Literature DB >> 17067622

Effects of Cilazapril on atrial electrical, structural and functional remodeling in atrial fibrillation dogs.

Yue Li1, Weimin Li, Baofeng Yang, Wei Han, Deli Dong, Jingyi Xue, Baoxin Li, Shusen Yang, Li Sheng.   

Abstract

BACKGROUND AND
PURPOSE: The effects of angiotensin-converting enzyme inhibitor on long-term atrial electrophysiologic and structural remodeling are still unclear. The purpose of this study is to investigate the effects of Cilazapril on atrial electrical, structural, and functional remodeling in atrial fibrillation (AF) dogs induced by chronic rapid atrial pacing.
METHODS: Twenty dogs were randomly divided into sham-operated group (n = 6), control group (n = 7), and Cilazapril group (n = 7). One thin silicon plaque containing 4 pairs of electrodes was sutured to each atrium. A pacemaker was implanted in a subcutaneous pocket and attached to a screw-in epicardial lead in the right atrial appendage. The dogs in control group and Cilazapril group were paced at 400 beats per minute for 6 weeks. The dogs in Cilazapril group received Cilazapril (0.5 mg x kg(-1) x d(-1)) 1 week before rapid atrial pacing until pacing stop. Before and after 6-week rapid atrial pacing, atrial effective refractory period (AERP) at 8 sites, AERP dispersion, intraatrium conduction time, inducibility, and duration of AF were measured. Transthoracic and transesophageal echocardiographic examinations included left atrium (LA) maximal volume, LA minimal volume, LA ejection fraction, left atrial appendage (LAA) maximal volume, LAA minimal volume, LAA ejection fraction, LAA maximal forward flow velocity, and LAA minimal backward flow velocity were performed. Atrial collagen volume fraction was analyzed by Masson staining.
RESULTS: After 6-week rapid atrial pacing, although there was no significant difference in AERP shortening and AERP rate adaptation reduction between the control group and the Cilazapril group, the inducibility and duration of AF were found to be dramatically lower in the Cilazapril group than those in the control group (AF inducibility, 65.7% vs 95.7%, P < .05; AF duration, 531.5 +/- 301.2 vs 1432.2 +/- 526.5 s, P < .01). The post-tachycardia intraatrium conduction times after 6 weeks with Cilazapril were significantly shorter than those in the control group. Cliazapril could partially prevent AERP dispersion increase induced by chronic rapid atrial pacing. Compared with the control group, the LA and LAA volumes were significantly smaller; LA ejection fraction, LAA ejection fraction, LAA maximal forward flow velocity, and LAA minimal backward flow velocity were dramatically higher in the Cilazapril group. The Cilazapril group had a significantly lower percentage of interstitial fibrosis than the control group.
CONCLUSIONS: Cilazapril can suppress structural and functional remodeling and prevent the induction and promotion of AF in chronic rapid atrial pacing dogs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17067622     DOI: 10.1016/j.jelectrocard.2006.04.001

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  13 in total

Review 1.  Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation: A Systematic Review of the Published Data.

Authors:  Karen P Phillips
Journal:  J Atr Fibrillation       Date:  2013-10-31

Review 2.  Atrial fibrosis and the mechanisms of atrial fibrillation.

Authors:  Thomas H Everett; Jeffrey E Olgin
Journal:  Heart Rhythm       Date:  2006-12-28       Impact factor: 6.343

Review 3.  The Atrium in Atrial Fibrillation - A Clinical Review on How to Manage Atrial Fibrotic Substrates.

Authors:  Pedro Silva Cunha; Sérgio Laranjo; Jordi Heijman; Mário Martins Oliveira
Journal:  Front Cardiovasc Med       Date:  2022-07-04

4.  Effect of Angiotensin converting enzyme inhibitors and Angiotensin receptor blockers on patients following ablation of atrial fibrillation.

Authors:  Jeong-Hwan Park; Yong-Seog Oh; Ji-Hoon Kim; Woo-Baek Chung; Su-Sung Oh; Dong-Hyun Lee; Yun-Seok Choi; Woo-Seung Shin; Chul-Soo Park; Ho-Joong Youn; Wook-Sung Chung; Man-Young Lee; Ki-Bae Seung; Tae-Ho Rho; Jae-Hyung Kim; Soon-Jo Hong
Journal:  Korean Circ J       Date:  2009-05-28       Impact factor: 3.243

Review 5.  Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets.

Authors:  Ya-Hui Ding; Yuan Ma; Lin-Yan Qian; Qiang Xu; Li-Hong Wang; Dong-Sheng Huang; Hai Zou
Journal:  Oncotarget       Date:  2017-07-24

6.  Metoprolol prevents chronic obstructive sleep apnea-induced atrial fibrillation by inhibiting structural, sympathetic nervous and metabolic remodeling of the atria.

Authors:  Li Sun; Sen Yan; Xiaoyu Wang; Shiqi Zhao; Hui Li; Yike Wang; Shuang Lu; Xinwen Dong; Jing Zhao; Shengzhu Yu; Minghui Li; Yue Li
Journal:  Sci Rep       Date:  2017-11-02       Impact factor: 4.379

Review 7.  Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.

Authors:  Gerald V Naccarelli; Frank Peacock
Journal:  Vasc Health Risk Manag       Date:  2009-09-18

8.  Cardiac Magnetic Resonance-Measured Left Atrial Volume and Function and Incident Atrial Fibrillation: Results From MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Mohammadali Habibi; Sanaz Samiei; Bharath Ambale Venkatesh; Anders Opdahl; Thomas M Helle-Valle; Mytra Zareian; Andre L C Almeida; Eui-Young Choi; Colin Wu; Alvaro Alonso; Susan R Heckbert; David A Bluemke; João A C Lima
Journal:  Circ Cardiovasc Imaging       Date:  2016-08       Impact factor: 7.792

Review 9.  Interatrial block: a virtual pandemic requiring attention.

Authors:  Raman Mehrzad; David H Spodick
Journal:  Iran J Med Sci       Date:  2014-03

Review 10.  Interatrial block in the modern era.

Authors:  Lovely Chhabra; Ramprakash Devadoss; Vinod K Chaubey; David H Spodick
Journal:  Curr Cardiol Rev       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.